货号:A951815
同义名:
beta-拉帕醌
/ ARQ-501; NSC-26326
β-Lapachone是一种天然存在的醌类化合物,从拉帕乔树(Tabebuia avellanedae)树皮中获得,具有抗癌化学预防特性,并且是 IDO1 的强效抑制剂(IC50 = 0.44 μM)。


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | Topo I ↓ ↑ | Topo II ↓ ↑ | Topo IV ↓ ↑ | Topoisomerase ↓ ↑ | 其他靶点 | 纯度 | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ellagic acid | ✔ | 98% | |||||||||||||||||
| β-Lapachone | ✔ | 99%+ | |||||||||||||||||
| (s)-10-hydroxycamptothecin | ✔ | 98+% | |||||||||||||||||
| Camptothecin |
++
Topo I, IC50: 0.68 μM |
98% | |||||||||||||||||
| Betulinic acid |
++
Eukaryotic topoisomerase I, IC50: 5 μM |
98% | |||||||||||||||||
| Topotecan |
++++
Topo I (DU-145 Luc cells), IC50: 2 nM Topo I (MCF-7 Luc cells), IC50: 13 nM |
98% | |||||||||||||||||
| Irinotecan HCl Trihydrate | ✔ | 98% | |||||||||||||||||
| SN-38 | ✔ | 98% | |||||||||||||||||
| Levofloxacin hydrate | ✔ | 98% | |||||||||||||||||
| Dexrazoxane | ✔ | 99%+ | |||||||||||||||||
| Ofloxacin | ✔ | 98+% | |||||||||||||||||
| Enoxacin | ✔ | 99%+ | |||||||||||||||||
| Flumequine |
+
Topo II, IC50: 15 μM |
98% | |||||||||||||||||
| Levofloxacin | ✔ | 97% | |||||||||||||||||
| Etoposide | ✔ | 98% | |||||||||||||||||
| Pefloxacin mesylate dihydrate | ✔ | 99.5% | |||||||||||||||||
| Marbofloxacin | ✔ | 98+% | |||||||||||||||||
| Voreloxin HCl | ✔ | 98% | |||||||||||||||||
| Mitoxantrone 2HCl | ✔ | PKC | 98% | ||||||||||||||||
| Nalidixic acid | ✔ | 98% | |||||||||||||||||
| Doxorubicin | ✔ | 97% | |||||||||||||||||
| Novobiocin sodium | ✔ | 95% | |||||||||||||||||
| Amonafide | ✔ | 99%+ | |||||||||||||||||
| Pirarubicin | ✔ | 98%+ | |||||||||||||||||
| Idarubicin HCl |
+++
Topo II (MCF-7 cells), IC50: 3.3 ng/mL |
99%+ | |||||||||||||||||
| Genistein | ✔ | EGFR | 98% | ||||||||||||||||
| Teniposide | ✔ | 98% | |||||||||||||||||
| Moxifloxacin | ✔ | 98% | |||||||||||||||||
| Ciprofloxacin | ✔ | 98% | |||||||||||||||||
| Clinafloxacin | ✔ | 99% | |||||||||||||||||
| Gatifloxacin | ✔ | 98% | |||||||||||||||||
| Daunorubicin HCl |
+++
DNA synthesis, Ki: 20 nM |
98% | |||||||||||||||||
| Epirubicin HCl | ✔ | 99%+ | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 靶点 |
|
| 描述 | β-Lapachone functions as a topoisomerase I inhibitor. At a concentration of 25 μM, β-Lapachone inhibits camptothecin-induced DNA cleavage [1]. Lapachone (at concentrations ranging from 10 to 40 μM) significantly diminishes the colony-forming ability of CHO cells and demonstrates cytotoxicity during the S phase. Additionally, β-Lapachone induces substantial DNA strand breaks in CHO cells at concentrations exceeding 10 μM [2]. β-Lapachone (10 μM) inhibits JCPyV replication in IMR-32 cells. β-Lapachone at 1.0 μM significantly impacts JCPyV propagation in JCI cells. Moreover, β-Lapachone at concentrations ranging from 0.01 to 0.1 μM inhibits VP1 production in JCI cells [4]. |
| 体内研究 | β-Lapachone (0.066%) mitigates cisplatin-induced renal injury, and its combination with cisplatin enhances this effect in mice. Additionally, β-Lapachone increases the expression of the Mre11-Rad50-Nbs1 (MRN) complex in mice [3]. |
| 体外研究 | β-Lapachone functions as a topoisomerase I inhibitor. At a concentration of 25 μM, β-Lapachone inhibits camptothecin-induced DNA cleavage [1]. Lapachone (at concentrations ranging from 10 to 40 μM) significantly diminishes the colony-forming ability of CHO cells and demonstrates cytotoxicity during the S phase. Additionally, β-Lapachone induces substantial DNA strand breaks in CHO cells at concentrations exceeding 10 μM [2]. β-Lapachone (10 μM) inhibits JCPyV replication in IMR-32 cells. β-Lapachone at 1.0 μM significantly impacts JCPyV propagation in JCI cells. Moreover, β-Lapachone at concentrations ranging from 0.01 to 0.1 μM inhibits VP1 production in JCI cells [4]. |
| Concentration | Treated Time | Description | References | |
| BT549 | 0.5 μM | 48 h | β-lapachone significantly enhanced the sensitivity of BT549 cells to phenformin, reducing tumor cell proliferation. | Nat Commun. 2021 Jun 3;12(1):3299. |
| BT474 | 1.0 μM | 48 h | β-lapachone significantly enhanced the sensitivity of BT474 cells to phenformin, reducing tumor cell proliferation. | Nat Commun. 2021 Jun 3;12(1):3299. |
| MDA-MB-231 | 0.5 μM | 48 h | β-lapachone significantly enhanced the sensitivity of MDA-MB-231 cells to phenformin, reducing tumor cell proliferation. | Nat Commun. 2021 Jun 3;12(1):3299. |
| LNCaP cells | 1–5 μM | 4 h | Induced apoptosis, observed G0/G1 phase block and increased apoptotic cell populations | Cancer Res. 1995 Sep 1;55(17):3706-11. |
| PC-3 cells | 1–5 μM | 4 h | Induced apoptosis, observed G0/G1 phase block and increased apoptotic cell populations | Cancer Res. 1995 Sep 1;55(17):3706-11. |
| DU-145 cells | 1–5 μM | 4 h | Induced apoptosis, observed G0/G1 phase block and increased apoptotic cell populations | Cancer Res. 1995 Sep 1;55(17):3706-11. |
| HL-60 cells | ≥0.5 μM | 4 h | Induced apoptosis, observed 180-200 bp oligonucleosome DNA laddering and apoptotic cells via flow cytometry | Cancer Res. 1995 Sep 1;55(17):3706-11. |
| MDA-MB-231 cells | 10 μM | 2 h | To evaluate the effect of β-Lapachone on PP-InsP levels in NQO1-deficient cells, the results showed that β-Lapachone did not affect 5-PP-InsP5 levels but significantly reduced ATP levels. | Proc Natl Acad Sci U S A. 2023 Aug 22;120(34):e2306868120. |
| HCT116 cells | 2.5 μM, 5 μM, or 10 μM | 2 h | To evaluate the effect of β-Lapachone on PP-InsP levels, the results showed that β-Lapachone dose-dependently decreased PP-InsP levels, while InsP6 levels remained stable. | Proc Natl Acad Sci U S A. 2023 Aug 22;120(34):e2306868120. |
| MDA-MB-231 cells | 10 μM | 2 h | In MDA-MB-231 cells, which lack NQO1, β-lapachone did not reduce PP-InsP levels, but ATP levels dropped significantly. | Proc Natl Acad Sci U S A. 2023 Aug 22;120(34):e2306868120. |
| MDA-MB-231 breast cancer cells | 6 μM | 2 h | To evaluate the cytotoxicity of β-Lapachone micelles on NQO1-overexpressing cells, results showed more than 50% cell death in NQO1+ cells at a 6 μM dose. | J Control Release. 2007 Oct 8;122(3):365-74. |
| DU-145 prostate cancer cells | 6 μM | 2 h | To evaluate the cytotoxicity of β-Lapachone micelles on NQO1-overexpressing cells, results showed more than 50% cell death in NQO1+ cells at a 6 μM dose. | J Control Release. 2007 Oct 8;122(3):365-74. |
| H596 non-small cell lung cancer cells | 5 μM, 10 μM | 2 h | To evaluate the cytotoxicity of β-Lapachone micelles on NQO1-overexpressing cells, results showed 26% and 85% cell death in NQO1+ cells at 5 μM and 10 μM doses, respectively. | J Control Release. 2007 Oct 8;122(3):365-74. |
| shNQO1 A549 cells | 10 μM | 4 h | In shNQO1 A549 cells, β-lap had a weaker inhibitory effect on NF-κB, indicating that NQO1 plays a crucial role in β-lap-mediated suppression of NF-κB activation. | Exp Mol Med. 2010 May 31;42(5):327-34. |
| A549 human lung cancer cells | 10 μM | 4 h | Suppressed radiation-induced NF-κB activation, almost completely abrogated NF-κB DNA binding activity, and inhibited the transcription of NF-κB target genes. | Exp Mol Med. 2010 May 31;42(5):327-34. |
| IMR-90 fibroblasts | >40 µM | IMR-90 fibroblasts were resistant to the cytotoxic effects of β-Lapachone. | Proc Natl Acad Sci U S A. 2007 Jul 10;104(28):11832-7. | |
| A549 NSCLC cells | 2.5 µM | 2 h | β-Lapachone killed A549 cells in an NQO1-dependent manner, inducing ROS formation, DNA damage, PARP-1 hyperactivation, NAD+/ATP depletion, and apoptosis. | Proc Natl Acad Sci U S A. 2007 Jul 10;104(28):11832-7. |
| H596 NSCLC cells | 4 µM | 2 h | β-Lapachone killed NSCLC cells in an NQO1-dependent manner, inducing ROS formation, DNA damage, PARP-1 hyperactivation, NAD+/ATP depletion, and apoptosis. | Proc Natl Acad Sci U S A. 2007 Jul 10;104(28):11832-7. |
| CHEF/18A cells | 4 μM | 5 h | β-Lapachone inhibited potentially lethal DNA damage repair (PLDR) processes, thereby reducing x-ray-induced cell transformation. At equivalent survival levels, β-Lapachone treatment resulted in an 8-fold decrease in transformation frequency. | Proc Natl Acad Sci U S A. 1989 Jul;86(13):4963-7. |
| Administration | Dosage | Frequency | Description | References | ||
| Mice | MDA-MB-231 mammary tumor model | Intraperitoneal injection | 25 mg/kg | Β-lapachone every 2 days, phenformin daily, continuous treatment | Combined β-lapachone and phenformin treatment significantly inhibited MDA-MB-231 mammary tumor growth and increased oxidative damage in mammary tumors. | Nat Commun. 2021 Jun 3;12(1):3299. |
| Dose | Rat: 40 mg/kg[3] (p.o.); 1.5 mg/kg[3] (i.v.) Mice: 5 mg/kg[4] (i.v.); 70 mg/kg - 80 mg/kg[4] (p.o.); 1.25 mg/kg - 5 mg/kg[5] (i.p.), 50 mg/kg[6] (i.p., BID) | ||||||||||||||||||
| Administration | p.o., i.v., i.p. | ||||||||||||||||||
| Pharmacokinetics |
|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT03575078 | Lymphoma | Phase 1 | Not yet recruiting | August 23, 2023 | - |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
4.13mL 0.83mL 0.41mL |
20.64mL 4.13mL 2.06mL |
41.28mL 8.26mL 4.13mL |
|
| CAS号 | 4707-32-8 |
| 分子式 | C15H14O3 |
| 分子量 | 242.27 |
| SMILES Code | O=C1C(CCC(C)(C)O2)=C2C3=CC=CC=C3C1=O |
| MDL No. | MFCD01712233 |
| 别名 | beta-拉帕醌 ;ARQ-501; NSC-26326; SL 11001; NSC 629749; Beta-Lapachone |
| 运输 | 蓝冰 |
| InChI Key | QZPQTZZNNJUOLS-UHFFFAOYSA-N |
| Pubchem ID | 3885 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry,2-8°C |
| 溶解方案 |
DMSO: 25 mg/mL(103.19 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 无水乙醇: 8 mg/mL(33.02 mM),配合低频超声助溶,注意:无水乙醇开封后,易挥发,也会吸收空气中的水分,导致溶解能力下降,请避免使用开封较久的乙醇 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1